SOMERSET, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in health care technology solutions for medical practices and health systems nationwide, is pleased to highlight its strategic partnership with U.S. Physiatry (USP), a prominent physiatry service provider operating in 20 U.S. states. This collaborative alliance, in effect since 2016, has recently seen remarkable growth and improvements, resulting in enhanced healthcare services for patients and optimized operations for both organizations.
USP, specializing in physiatry services at inpatient and outpatient facilities, including hospitals, rehabilitation centers, skilled nursing homes, and long-term acute care hospitals, has experienced a transformational shift in its partnership with CareCloud. With no office locations, USP relies heavily on CareCloud's technology-enabled revenue cycle management (RCM) services to streamline their financial processes and optimize their patient care services.
CareCloud RCM is a technology-enabled solution that streamlines administrative tasks and enables financial success for practices. It offers a dedicated team of RCM professionals who will handle billing, claims management, and revenue optimization. It also helps to reduce days in accounts receivable, automate manual processes, and improve revenue capture. Additionally, practices can gain real-time insights into revenue cycle performance with powerful analytics tools.
The CareCloud and USP partnership is maximized by the use of CareCloud's Patient Call Center add-on service, which has proven to be invaluable in managing patient communications and engagement. Some of the notable benefits that U.S. Physiatry has gained from its partnership with CareCloud include:
"The U.S. Physiatry and CareCloud partnership has transformed significantly over the past year, leading to improved communication, streamlined RCM processes, and enhanced efficiency for USP,” said Joe Stork, president of USP. “This collaboration has boosted our RCM, optimized workflows, and improved insurance accounts receivable. CareCloud's knowledge of RCM has lightened the administrative workload for U.S. Physiatry staff, allowing us to focus more on patient care."
CareCloud and U.S. Physiatry's partnership exemplifies the potential for collaboration between technology providers and healthcare organizations to drive positive outcomes for both patients and providers. The shared commitment to delivering high-quality healthcare services and improving operational efficiencies is paving the way for continued success in the future.
To learn more about CareCloud’s comprehensive suite of technology-enabled services and solutions, visit carecloud.com/solutions.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
Company Contact:
Bill Korn
Chief Strategy Officer
CareCloud
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Asher Dewhurst
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
Alexis Feinberg
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.25 |
Daily Change: | -0.01 -0.79 |
Daily Volume: | 645,400 |
Market Cap: | US$20.320M |
April 07, 2025 April 02, 2025 March 26, 2025 March 13, 2025 January 28, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load